SCHEMBL422337

SCHEMBL422337

O=C(O)Cc1cccc(-c2ccoc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
PTGS2 P35354 1/20 0.48
SERPINE1 P05121 3/20 0.47
ENPP2 Q13822 1/20 0.47
AKR1B1 P15121 1/20 0.46
CNR1 P21554 1/20 0.45
ABCC4 O15439 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
PTGS1 P23219 1/20 0.44
HTT P42858 1/20 0.44
PLA2G10 O15496 1/20 0.44
PLA2G2A P14555 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420379 0.84 PPARD (0.54) SERPINE1AKR1B1PLA2G10PLA2G2ASYK
SCHEMBL28032595 0.82 LMNA (0.63) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL538397 0.81 ABCC4 (0.67) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15349962 0.80 FYN (0.54) SERPINE1ENPP2CNR1LMNA
SCHEMBL6511662 0.80 ABCC4 (0.60) PTGS2AKR1B1ABCC4LMNAGAA
SCHEMBL1016040 0.78 SERPINE1 (0.62) SERPINE1CNR1LMNATSHR
SCHEMBL7030142 0.78 ACMSD (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Methyl Alcohol SCHEMBL7855784 0.78 ABCC4 (0.62) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL9251496 0.78 ABCC4 (0.74) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1013715 0.76 CSNK2A1 (0.53) SERPINE1ENPP2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
CN-102378753-A Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO LTD 2012-03-14 CN disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed
EP-1471923-A4 AMIDO MACROLIDES KOSAN BIOSCIENCES INC (US) 2006-01-11 EP disclosed
US-6939861-B2 Amido macrolides KOSAN BIOSCIENCES, INC. (US) 2005-09-06 US disclosed
EP-1471923-A1 AMIDO MACROLIDES Kosan Biosciences, Inc. (US) 2004-11-03 EP disclosed
US-20030199458-A1 Amido macrolides KOSAN BIOSCIENCES, INC. 2003-10-23 US disclosed
WO-2003061671-A1 AMIDO MACROLIDES KOSAN BIOSCIENCES, INC. (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 GRIN2D 4864/4885GRIN3B 4615/4885GRIN1 3419/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 GRIN2D 4864/4885GRIN3B 4615/4885GRIN1 3419/4885
US-20030199458-A1 Amido macrolides PCSK9, ABCB4, PCSK7 GRIN2D 4340/4885GRIN3B 4231/4885GRIN1 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.